Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
49.75 PLN | 0.00% | -6.13% | -13.48% |
Sales 2024 * | 152M 37.55M | Sales 2025 * | 218M 53.8M | Capitalization | 1.15B 284M |
---|---|---|---|---|---|
Net income 2024 * | -161M -39.82M | Net income 2025 * | -119M -29.43M | EV / Sales 2024 * | 7.09 x |
Net cash position 2024 * | 73.62M 18.21M | Net Debt 2025 * | 18.41M 4.55M | EV / Sales 2025 * | 5.37 x |
P/E ratio 2024 * |
-12.4
x | P/E ratio 2025 * |
-11.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.75% |
Latest transcript on Ryvu Therapeutics S.A.
1 week | -6.13% | ||
Current month | -9.87% | ||
1 month | -12.41% | ||
3 months | -10.04% | ||
6 months | -24.51% | ||
Current year | -13.48% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 06-12-31 | |
Hendrik Nogai
CTO | Chief Tech/Sci/R&D Officer | - | 22-01-31 |
Chief Operating Officer | 38 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | - | |
Scott Fields
BRD | Director/Board Member | 69 | 23-06-13 |
Thomas Turalski
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 49.75 | 0.00% | 2 880 |
24-04-24 | 49.75 | -2.07% | 4,107 |
24-04-23 | 50.8 | -0.39% | 5,472 |
24-04-22 | 51 | -3.59% | 7,527 |
24-04-19 | 52.9 | -0.19% | 4,351 |
Delayed Quote Warsaw S.E., April 25, 2024 at 10:20 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.48% | 284M | |
-2.77% | 104B | |
+0.74% | 97.42B | |
+1.37% | 22.2B | |
-18.07% | 21.23B | |
-10.67% | 18.33B | |
-42.33% | 16.35B | |
-18.11% | 15.06B | |
+5.04% | 13.98B | |
+27.88% | 11.66B |
- Stock Market
- Equities
- RVU Stock